Corresponding Author: John S. Gill, MD, MS, St Paul’s Hospital, 1081 Burrard St, Providence Building Ward 6a, Vancouver, BC V6Z 1Y6, Canada (jgill@providencehealth.bc.ca).
Accepted for Publication: November 27, 2020.
Published Online: February 3, 2021. doi:10.1001/jamasurg.2020.6929
Author Contributions: Drs Gill and Clark had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Woodle and Gill contributed equally as co–first authors.
Concept and design: Woodle, Gill, First.
Acquisition, analysis, or interpretation of data: Woodle, Clark, Stewart, Alloway, First.
Drafting of the manuscript: Woodle, Gill, Clark, First.
Critical revision of the manuscript for important intellectual content: Woodle, Clark, Stewart, Alloway, First.
Statistical analysis: Clark, Stewart.
Obtained funding: Woodle.
Administrative, technical, or material support: Woodle, Stewart, Alloway, First.
Supervision: Woodle, Gill.
Conflict of Interest Disclosures: Dr Woodle reports grants from Astellas Pharma and grants and personal fees from Sanofi during the conduct of the study. Dr Gill reports grants and personal fees from Astellas Pharma outside the submitted work. Dr Alloway reports grants from Astellas Pharma during the conduct of the study. No other disclosures were reported.
Funding/Support: Dr Gill is supported by a foundation grant from the Canadian Institutes of Health Research.
Role of the Funder/Sponsor: The funding organization and original trial sponsor (Astellas) had on role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as official policy of the US government.
Additional Contributions: We wish to acknowledge the original trial sponsor, Astellas Pharma, who supported the original trial by making the original trial data set available, the transplant centers that participated in the original trial, and Aparna Sadavarte, MS, at United Network of Organ Sharing who identified the trial participants in the Organ Procurement and Transplant Network registry. No compensation was received outside their standard salary.
1.Hricik
DE , O’Toole
MA , Schulak
JA , Herson
J . Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis.
J Am Soc Nephrol. 1993;4(6):1300-1305.
PubMedGoogle Scholar 2.Kasiske
BL , Chakkera
HA , Louis
TA , Ma
JZ . A meta-analysis of immunosuppression withdrawal trials in renal transplantation.
J Am Soc Nephrol. 2000;11(10):1910-1917.
PubMedGoogle Scholar 3.Sinclair
NR ; The Canadian Multicentre Transplant Study Group. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts.
CMAJ. 1992;147(5):645-657.
PubMedGoogle Scholar 5.Woodle
ES , First
MR , Pirsch
J , Shihab
F , Gaber
AO , Van Veldhuisen
P ; Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.
Ann Surg. 2008;248(4):564-577. doi:
10.1097/SLA.0b013e318187d1daPubMedGoogle ScholarCrossref 6.Rizzari
MD , Suszynski
TM , Gillingham
KJ ,
et al. Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation.
Clin J Am Soc Nephrol. 2012;7(3):494-503. doi:
10.2215/CJN.08630811PubMedGoogle ScholarCrossref 11.Kasiske
BL , Zeier
MG , Chapman
JR ,
et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary.
Kidney Int. 2010;77(4):299-311. doi:
10.1038/ki.2009.377Google ScholarCrossref 17.Halloran
PF , Reeve
JP , Pereira
AB , Hidalgo
LG , Famulski
KS . Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies.
Kidney Int. 2014;85(2):258-264. doi:
10.1038/ki.2013.300PubMedGoogle ScholarCrossref 19.Bouatou
Y , Viglietti
D , Pievani
D ,
et al. Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection.
Am J Transplant. 2019;19(7):1972-1988. doi:
10.1111/ajt.15299PubMedGoogle Scholar 23.Vincenti
F , Schena
FP , Paraskevas
S , Hauser
IA , Walker
RG , Grinyo
J ; FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients.
Am J Transplant. 2008;8(2):307-316. doi:
10.1111/j.1600-6143.2007.02057.xPubMedGoogle ScholarCrossref 24.Gallagher
MP , Hall
B , Craig
J , Berry
G , Tiller
DJ , Eris
J ; Australian Multicenter Trial of Cyclosporine Withdrawal Study Group and the ANZ Dialysis and Transplantation Registry. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results.
Transplantation. 2004;78(11):1653-1660. doi:
10.1097/01.TP.0000144181.47045.FEPubMedGoogle ScholarCrossref